Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties

References

• Imenshahidi M, Hosseinzadeh H. Berberine and barberry (Berberis vulgaris): a clinical review. Phytother Res. 2019;33(3):504–523.
   PubMed Web of Science ®Google Scholar
• Belwal T, Bisht A, Devkota HP, et al. Phytopharmacology and clinical updates of berberis species against diabetes and other metabolic diseases. Front Pharmacol. 2020;11:41.
   PubMed Web of Science ®Google Scholar
• Branton A. The use of novel and unique biofield energy healing treatment for the improvement of poorly bioavailable compound, berberine in male Sprague Dawley rats. Am J Clin Exp Med. 2017;5(4):138–144.
   Google Scholar
• Yuan NN, Cai CZ, Wu MY, et al. Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies. BMC Complement Altern Med. 2019;19(1):109. DOI:10.1186/s12906-019-2510-z
   PubMedGoogle Scholar
• Tan XS, Ma JY, Feng R, et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS ONE. 2013;8(10):e77969. DOI:10.1371/journal.pone.0077969
   PubMed Web of Science ®Google Scholar
• Wang K, Feng X, Chai L, et al. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab Rev. 2017;49(2):139–157. DOI:10.1080/03602532.2017.1306544
   PubMed Web of Science ®Google Scholar
• Chen W, Miao YQ, Fan DJ, et al. Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats. AAPS Pharm Sci Tech. 2011;12(2):705–711. DOI:10.1208/s12249-011-9632-z
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen Y, Deng J, et al. Solid dispersion of berberine–phospholipid complex/TPGS 1000/SiO2: preparation, characterization and in vivo studies. Int J Pharm. 2014;465(1–2):306–316. DOI:10.1016/j.ijpharm.2014.01.023
   PubMed Web of Science ®Google Scholar
• Liu CS, Zheng YR, Zhang YF, et al. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016;109:274–282.
   PubMed Web of Science ®Google Scholar
• Kumar S, Bhargava D, Thakkar A, et al. Drug carrier systems for solubility enhancement of BCS class II drugs: a critical review. Crit Rev Ther Drug Carrier Syst. 2013;30(3):217–256. DOI:10.1615/CritRevTherDrugCarrierSyst.2013005964
   PubMed Web of Science ®Google Scholar
• Miyazaki S, Oshiba M, Nadai T. Dissolution properties of salt forms of berberine. Chem Pharm Bull. 1981;29(3):883–886.
   Web of Science ®Google Scholar
• Takács-Novák K, Szász G. Ion-pair partition of quaternary ammonium drugs: the influence of counter ions of different lipophilicity, size, and flexibility. Pharm Res. 1999;16(10):1633–1638.
   PubMed Web of Science ®Google Scholar
• Chae HW, Kim IW, Jin HE, et al. Effect of ion-pair formation with bile salts on the in vitro cellular transport of berberine. Arch Pharm Res. 2008;31(1):103–110. DOI:10.1007/s12272-008-1127-4
   PubMed Web of Science ®Google Scholar
• Battu SK, Repka MA, Maddineni M, et al. Physicochemical characterization of berberine chloride: a perspective in the development of a solution dosage form for oral delivery. AAPS Pharm Sci Tech. 2010;11(3):1466–1475. DOI:10.1208/s12249-010-9520-y
   PubMed Web of Science ®Google Scholar
• Cui HX, Hu YN, Li JW, et al. Preparation and evaluation of antidiabetic agents of berberine organic acid salts for enhancing the bioavailability. Molecules. 2018;24(1):103. DOI:10.3390/molecules24010103
   PubMed Web of Science ®Google Scholar
• Maeng HJ, Yoo HJ, Kim IW, et al. P-Glycoprotein–mediated transport of berberine across caco-2 cell monolayers. J Pharm Sci. 2002;91(12):2614–2621. DOI:10.1002/jps.10268
   PubMed Web of Science ®Google Scholar
• Pan GY, Wang GJ, Liu XD, et al. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002;91(4):193–197. DOI:10.1034/j.1600-0773.2002.t01-1-910403.x
   PubMedGoogle Scholar
• Zhang YT, Yu YQ, Yan XX, et al. Different structures of berberine and five other protoberberine alkaloids that affect P-glycoprotein-mediated efflux capacity. Acta Pharmacol Sin. 2019;40(1):133–142. DOI:10.1038/s41401-018-0183-7
   PubMed Web of Science ®Google Scholar
• Ma JY, Feng R, Tan XS, et al. Excretion of berberine and its metabolites in oral administration in rats. J Pharm Sci. 2013;102(11):4181–4192. DOI:10.1002/jps.23718
   PubMed Web of Science ®Google Scholar
• Feng X, Wang K, Cao S, et al. Pharmacokinetics and excretion of berberine and its nine metabolites in rats. Front Pharmacol. 2021;11:594852.
   PubMed Web of Science ®Google Scholar
• Liu YT, Hao HP, Xie HG, et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab Dispos. 2010;38(10):1779–1784. DOI:10.1124/dmd.110.033936
   PubMed Web of Science ®Google Scholar
• Murakami T, Bodor E, Bodor N. Modulation of expression/function of intestinal P-glycoprotein under disease states. Expert Opin Drug Metab Toxicol. 2020;16(1):59–78.
   PubMed Web of Science ®Google Scholar
• Murakami T, Bodor E, Bodor N. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs. Expert Opin Drug Metab Toxicol. 2021;17(5):555–580.
   PubMed Web of Science ®Google Scholar
• Zhang X, Han Y, Huang W, et al. The influence of the gut microbiota on the bioavailability of oral drugs. Acta Pharm Sin B. 2021;11(7):1789–1812. DOI:10.1016/j.apsb.2020.09.013
   PubMed Web of Science ®Google Scholar
• Xu L, Zhang Y, Xue X, et al. A phase I trial of berberine in Chinese with ulcerative colitis. Cancer Prev Res (Phila). 2020;13(1):117–126. DOI:10.1158/1940-6207.CAPR-19-0258
   PubMed Web of Science ®Google Scholar
• Petrangolini G, Corti F, Ronchi M, et al. Development of an innovative berberine food-grade formulation with an ameliorated absorption: in vitro evidence confirmed by healthy human volunteers pharmacokinetic study. Evid Based Complement Alternat Med. 2021;2021:7563889.
   PubMed Web of Science ®Google Scholar
• Cheng M, Liu R, Wu Y, et al. LC-MS/MS determination and urinary excretion study of seven alkaloids in healthy Chinese volunteers after oral administration of Shuanghua Baihe tablets. J Pharm Biomed Anal. 2016;118:89–95.
   PubMed Web of Science ®Google Scholar
• Wang W, Shen Q, Liang H, et al. Pharmacokinetic studies of novel berberine derivatives with ultra-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2016;1031:172–180.
   PubMed Web of Science ®Google Scholar
• Zuo F, Nakamura N, Akao T, et al. Pharmacokinetics of berberine and its main metabolites in conventional and pseudo germ-free rats determined by liquid chromatography/ion trap mass spectrometry. Drug Metab Dispos. 2006;34(12):2064–2072. DOI:10.1124/dmd.106.011361
   PubMed Web of Science ®Google Scholar
• Calvo A, Moreno E, Larrea E, et al. Berberine-loaded liposomes for the treatment of Leishmania infantum-infected BALB/c mice. Pharmaceutics. 2020;12(9):858. DOI:10.3390/pharmaceutics12090858
   PubMed Web of Science ®Google Scholar
• Persiani S, Sala F, Zangarini M, et al. Effect of food on the oral bioavailability of berberine and monacolin administered in combination in healthy male volunteers. J Pharm Pharmacol. 2014;2(12):703–712. DOI:10.17265/2328-2150/2014.12.003
   Google Scholar
• Wang Y, Tong Q, Shou JW, et al. Gut microbiota-mediated personalized treatment of hyperlipidemia using berberine. Theranostics. 2017;7(9):2443–2451. DOI:10.7150/thno.18290
   PubMed Web of Science ®Google Scholar
• Benet LZ. The Role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. J Pharm Sci. 2013;102(1):34–42.
   PubMed Web of Science ®Google Scholar
• Xu HY, Liu CS, Huang CL, et al. Nanoemulsion improves hypoglycemic efficacy of berberine by overcoming its gastrointestinal challenge. Colloids Surf B Biointerfaces. 2019;181:927–934.
   PubMed Web of Science ®Google Scholar
• Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008;4(7):923–939.
   PubMed Web of Science ®Google Scholar
• Murakami T. Absorption sites of orally administered drugs in the small intestine. Expert Opin Drug Discov. 2017;12(12):1219–1232.
   PubMed Web of Science ®Google Scholar
• Harwood MD, Zhang M, Pathak SM, et al. The regional-specific relative and absolute expression of gut transporters in adult Caucasians: a meta-analysis. Drug Metab Dispos. 2019;47(8):854–864. DOI:10.1124/dmd.119.086959
   PubMed Web of Science ®Google Scholar
• Ilyas Z, Perna S, Al-Thawadi S, et al. The effect of berberine on weight loss to prevent obesity: a systematic review. Biomed Pharmacother. 2020;127:110137.
   PubMed Web of Science ®Google Scholar
• Cui HM, Zhang Q-Y, Wang J-L, et al. Poor permeability and absorption affect the activity of four alkaloids from Coptis. Mol Med Rep. 2015;12(5):7160–7168. DOI:10.3892/mmr.2015.4288
   PubMed Web of Science ®Google Scholar
• Porru E, Franco P, Calabria D, et al. Combined analytical approaches to define biodistribution and biological activity of semi-synthetic berberrubine, the active metabolite of natural berberine. Anal Bioanal Chem. 2018;410(15):3533–3545. DOI:10.1007/s00216-018-0884-2
   PubMed Web of Science ®Google Scholar
• Xin HW, Tang X, Ouyang M, et al. Effects of berberine on pharmacokinetics of midazolam and rhodamine 123 in rats in vivo. Springerplus. 2016;5(1):380. DOI:10.1186/s40064-016-2013-z
   PubMedGoogle Scholar
• Dahan A, Amidon GL. Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm. 2009;6(1):19–28.
   PubMed Web of Science ®Google Scholar
• Zhang X, Qiu F, Jiang J, et al. Intestinal absorption mechanisms of berberine, palmatine, jateorhizine, and coptisine: involvement of P-glycoprotein. Xenobiotica. 2011;41(4):290–296. DOI:10.3109/00498254.2010.529180
   PubMed Web of Science ®Google Scholar
• Jing W, Safarpour Y, Zhang T, et al. Berberine upregulates P-glycoprotein in human Caco-2 cells and in an experimental model of colitis in the rat via activation of Nrf2-dependent mechanisms. J Pharmacol Exp Ther. 2018;366(2):332–340. DOI:10.1124/jpet.118.249615
   PubMed Web of Science ®Google Scholar
• Li Y, Ren G, Wang YX, et al. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J Transl Med. 2011;9(1):62. DOI:10.1186/1479-5876-9-62
   PubMedGoogle Scholar
• Martignoni M, Groothuis GM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875–894.
   PubMed Web of Science ®Google Scholar
• Qiu F, Zhu Z, Kang N, et al. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab Dispos. 2008;36(11):2159–2165. DOI:10.1124/dmd.108.021659
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metab Rev. 2011;43(4):476–498.
   PubMed Web of Science ®Google Scholar
• Wu X, Li Q, Xin H, et al. Effects of berberine on the blood concentration of cyclosporin a in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567–572. DOI:10.1007/s00228-005-0952-3
   PubMed Web of Science ®Google Scholar
• Qiu W, Jiang XH, Liu CX, et al. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res. 2009;23(11):1553–1558. DOI:10.1002/ptr.2808
   PubMed Web of Science ®Google Scholar
• Guo Y, Chen Y, Tan ZR, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213–217. DOI:10.1007/s00228-011-1108-2
   PubMed Web of Science ®Google Scholar
• Cai Y, Xin Q, Lu J, et al. A new therapeutic candidate for cardiovascular diseases: berberine. Front Pharmacol. 2021;12:631100.
   PubMed Web of Science ®Google Scholar
• Chitlange S, Kamble S, Deshkar S. Bioavailability of berberine: challenges and solutions. İ̇Istanbul J Pharmacy. 2021;51(1):141–153.
   Google Scholar
• Langhammer AJ, Nilsen OG. In vitro inhibition of human CYP1A2, CYP2D6, and CYP3A4 by six herbs commonly used in pregnancy. Phytother Res. 2014;28(4):603–610.
   PubMed Web of Science ®Google Scholar
• Noh K, Kang YR, Nepal MR, et al. Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs. Arch Pharm Res. 2017;40(12):1345–1355. DOI:10.1007/s12272-017-0986-y
   PubMed Web of Science ®Google Scholar
• Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity.Transl Res. 2017;179:204–222. DOI:10.1016/j.trsl.2016.08.002
   Google Scholar
• Alolga RN, Fan Y, Chen Z, et al. Significant pharmacokinetic differences of berberine are attributable to variations in gut microbiota between Africans and Chinese. Sci Rep. 2016;6(1):27671. DOI:10.1038/srep27671
   PubMedGoogle Scholar
• Zhang ZW, Cong L, Peng R, et al. Transformation of berberine to its demethylated metabolites by the CYP51 enzyme in the gut microbiota. J Pharm Anal. 2021;11(5):628–637. DOI:10.1016/j.jpha.2020.10.001
   PubMed Web of Science ®Google Scholar
• Wang X, Wang S, Ma J, et al. Pharmacokinetics in rats and tissue distribution in mouse of berberrubine by UPLC-MS/MS. J Pharm Biomed Anal. 2015;115:368–374.
   PubMed Web of Science ®Google Scholar
• Yang N, Sun RB, Chen XL, et al. In vitro assessment of the glucose-lowering effects of berberrubine-9-O-β-D-glucuronide, an active metabolite of berberrubine. Acta Pharmacol Sin. 2017;38(3):351–361. DOI:10.1038/aps.2016.120
   PubMed Web of Science ®Google Scholar
• Yang N, Sun R, Zhao Y, et al. High fat diet aggravates the nephrotoxicity of berberrubine by influencing on its pharmacokinetic profile. Environ Toxicol Pharmacol. 2016;46:319–327.
   PubMed Web of Science ®Google Scholar
• Yu XT, Xu YF, Huang YF, et al. Berberrubine attenuates mucosal lesions and inflammation in dextran sodium sulfate-induced colitis in mice. PLoS ONE. 2018;13(3):e0194069. DOI:10.1371/journal.pone.0194069
   PubMed Web of Science ®Google Scholar
• Bodor N, Brewster ME. Improved delivery through biological membranes XV - Sustained brain delivery of berberine. Eur J Med Chem. 1983;18:235–240.
   Web of Science ®Google Scholar
• Brewster ME, Bodor N. Improved delivery through biological membranes XVI. Enhancement of the brain-specificity of a dihydropyridine formed from pyridinium salt drug delivery system by controlled infusion. J Parenter Sci Technol. 1983;37:159–164.
   PubMedGoogle Scholar
• Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes. 2008;57:1414–1418.
   PubMed Web of Science ®Google Scholar
• Feng R, Shou JW, Zhao ZX, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155.
   PubMed Web of Science ®Google Scholar
• Moon JM, Ratliff KM, Hagele AM, et al. Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients. 2021;14:124.
   PubMedGoogle Scholar
• Bodor N, Farag HG, Brewster ME 3rd. Site-specific, sustained release of drugs to the brain. Science. 1981;214(4527):1370–1372.
   PubMed Web of Science ®Google Scholar
• Bodor N, Brewster ME. Problems of delivery of drugs to the brain. Pharmac Ther. 1983;19:337–386.
   Web of Science ®Google Scholar
• Zhao YH, Abraham MH, Le J, et al. Evaluation of rat intestinal absorption data and correlation with human intestinal absorption. Eur J Med Chem. 2003;38:233–243.
   PubMed Web of Science ®Google Scholar
• Ruan LP, Chen S, Yu BY, et al. Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. Eur J Med Chem. 2006;41:605–610.
   PubMed Web of Science ®Google Scholar
• Zakeri-Milani P, Valizadeh H, Tajerzadeh H, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 2007;10:368–379.
   PubMed Web of Science ®Google Scholar
• Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450. Crit Rev Toxicol. 1991;21:407–422.
   PubMed Web of Science ®Google Scholar